Robert W. Baird Trims Edwards Lifesciences (NYSE:EW) Target Price to $68.00

Edwards Lifesciences (NYSE:EW) had its price target decreased by Robert W. Baird from $73.00 to $68.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price objective points to a potential downside of 3.29% from the stock’s previous close.

EW has been the topic of a number of other research reports. Morgan Stanley reissued an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Stifel Nicolaus reduced their target price on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, July 25th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. lowered shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $105.00 to $72.00 in a report on Thursday, July 25th. Fifteen analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $75.71.

Edwards Lifesciences Trading Down 0.4 %

Shares of Edwards Lifesciences stock opened at $70.31 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a 50-day moving average of $68.04 and a 200-day moving average of $78.71. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market cap of $42.37 billion, a PE ratio of 30.31, a PEG ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the company earned $0.59 EPS. The business’s revenue was up 8.9% on a year-over-year basis. As a group, sell-side analysts forecast that Edwards Lifesciences will post 2.71 EPS for the current year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,099,238 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences during the second quarter worth $39,000. Versant Capital Management Inc lifted its holdings in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after buying an additional 326 shares during the period. Finally, HHM Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the second quarter valued at $55,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.